Arvinas Inc. (ARVN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Arvinas Inc. (ARVN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

17.20

-0.81 (-4.50%)

At close: Jan 14, 2025, 3:59 PM

17.30

0.58%

After-hours Jan 14, 2025, 05:13 PM EST

undefined% (undefined)

Bid	17.22
Market Cap	1.18B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.79
PE Ratio (ttm)	-3.59
Forward PE	n/a
Analyst	Buy

Ask	18.5
Volume	515,309
Avg. Volume (20D)	786,063
Open	18.06
Previous Close	18.01
Day's Range	17.09 - 18.39
52-Week Range	17.09 - 53.08
Beta	undefined

About ARVN

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 27, 2018

Employees 445

Stock Exchange NASDAQ

Ticker Symbol ARVN

Website https://www.arvinas.com

Analyst Forecast

According to 13 analyst ratings, the average rating for ARVN stock is "Buy." The 12-month stock price forecast is $60, which is an increase of 248.84% from the latest price.

Buy 92.31%

Hold 7.69%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Arvinas Inc. is scheduled to release its earnings on Feb 25, 2025, before market opens.
Analysts project revenue of $59.49M, reflecting a -238.03% YoY shrinking and earnings per share of -1.04, making a -58.89% decrease YoY.

Why Price Moved

2 months ago · Source

+0.58%

Arvinas shares are trading higher after the compan... Unlock content with Pro Subscription

9 months ago · Source

+1.44%

Arvinas shares are trading higher after the company entered a license agreement with Novartis for the development and commercialization of ARV-766 in prostate cancer treatment.

News

2 months ago · seekingalpha.com

Arvinas, Inc. (ARVN) Q3 2024 Earnings Call Transcript

Arvinas, Inc. (NASDAQ:ARVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jeff Ball - Chief Financial Officer John Houston - Chief Executive Officer, President and...

2 months ago · zacks.com

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to loss of $1.18 per share a year ago.